Difference between revisions of "Oprozomib (ONX-0912)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674605 NCI drug dictionary]: An orally bioavailable proteasome inhibitor with pot...") |
Warner-admin (talk | contribs) m (Warner-admin moved page Oprozomib (ONX 0912) to Oprozomib (ONX-0912) without leaving a redirect) |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674605 NCI drug dictionary]: An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Oprozomib inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. | From [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674605 NCI drug dictionary]: An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Oprozomib inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[Multiple myeloma]]== | + | ===[[Multiple myeloma]]=== |
# '''Abstract:''' Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD, MBA, Ju RueyJiuan Lee, PhD and Jesus G. Berdeja, MD. Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. ASH 2014 Abstract 34 [https://ash.confex.com/ash/2014/webprogram/Paper75523.html link to abstract] | # '''Abstract:''' Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD, MBA, Ju RueyJiuan Lee, PhD and Jesus G. Berdeja, MD. Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. ASH 2014 Abstract 34 [https://ash.confex.com/ash/2014/webprogram/Paper75523.html link to abstract] | ||
# '''Abstract:''' Parameswaran N. Hari, MD, Kenneth H. Shain, MD, PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD, MBA, Sandra J. Dixon, MS and Claudia Paba Prada, MD. Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. ASH 2014 Abstract 3453 [https://ash.confex.com/ash/2014/webprogram/Paper75409.html link to abstract] | # '''Abstract:''' Parameswaran N. Hari, MD, Kenneth H. Shain, MD, PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD, MBA, Sandra J. Dixon, MS and Claudia Paba Prada, MD. Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. ASH 2014 Abstract 3453 [https://ash.confex.com/ash/2014/webprogram/Paper75409.html link to abstract] | ||
| − | + | ==Also known as== | |
| − | [[Category: | + | *'''Code name:''' ONX-0912 |
| − | [[Category:Oral | + | |
| + | [[Category:Drugs]] | ||
| + | |||
| + | [[Category:Oral medications]] | ||
[[Category:Proteasome inhibitors]] | [[Category:Proteasome inhibitors]] | ||
| − | [[Category:Multiple myeloma medications]] | + | [[Category:Multiple myeloma medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 00:37, 29 July 2023
Mechanism of action
From NCI drug dictionary: An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Oprozomib inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth.
Preliminary data
Multiple myeloma
- Abstract: Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD, MBA, Ju RueyJiuan Lee, PhD and Jesus G. Berdeja, MD. Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. ASH 2014 Abstract 34 link to abstract
- Abstract: Parameswaran N. Hari, MD, Kenneth H. Shain, MD, PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD, MBA, Sandra J. Dixon, MS and Claudia Paba Prada, MD. Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. ASH 2014 Abstract 3453 link to abstract
Also known as
- Code name: ONX-0912